IPO
Eikon and Veradermics Announce IPO Targets Amid Biotech Market Optimism
Eikon Therapeutics; Veradermics; IPO; biotech; hair loss; cancer drugs; Nasdaq; NYSE
2026 IPO Train Keeps Chugging as AgomAb Therapeutics and SpyGlass Pharma File for Nasdaq Debuts
AgomAb Therapeutics; SpyGlass Pharma; IPO; Nasdaq; 2026 biotech IPOs; ontunisertib; bimatoprost IOL
Eikon Therapeutics Files for IPO Amid Biotech Rally Test
Eikon Therapeutics; IPO filing; biotech rally; cancer drugs; Nasdaq EIKN
Veradermics Files for $100 Million IPO to Advance Oral Minoxidil Hair Loss Treatment
Veradermics; IPO; hair loss; minoxidil; VDPHL01; Phase 3
Aktis Oncology’s 25% IPO jump lifts optimism for a biotech IPO rebound in 2026
Aktis Oncology IPO; AKTS; 2026 biotech IPOs; IPO bounce; radiopharmaceuticals; Eli Lilly backing; biotech capital markets; Nectin-4; B7-H3; IPO window 2026
VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026
venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment
VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026
venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment
VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026
venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment
VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026
venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment
Aktis Oncology Targets $181M-$209M in First Biotech IPO of 2026
Aktis Oncology; IPO; biotech; radiopharmaceutical; 2026; $181M; $200M